The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking studies, Gilead Sciences’ shot nearly eliminated new infections in people at high risk of HIV.

The drug could change the course of the AIDS epidemic. But the Trump administration has gutted the programs that might have paid for it in low-income countries.

The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to HIV-prevention infrastructure in the U.S.